CatalystWireBeta

Advanced Medical Solutions Group

AMS · AIM · Health Care · mcap £614m · 282.0p

Beta Briefing, track record and signals & risks are not ready for Advanced Medical Solutions Group yet.

We follow 967 UK small caps and every one of their announcements – often hundreds per company. 71 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 12:35

DateTypeAnnouncementDay
13 Oct 26 Publication of Financing Materials
H.B. Fuller publishes financing materials for recommended acquisition of AMS by cash scheme.
08 Oct 26 Routine Rule 2.9 Announcement
06 Oct 26 Publication of Financing Materials.
Financing materials for H.B. Fuller's recommended cash acquisition of AMS published for debt investors.
−0.2%
01 Oct 26 Holding Holding(s) in Company
30 Sep 26 Publication of Financing Materials
H.B. Fuller publishes financing materials for its recommended £294m cash acquisition of AMS.
+0.2%
23 Sep 26 Holding Holding(s) in Company
22 Sep 26 Routine Rule 2.9 Announcement
21 Sep 26 Routine Rule 2.9 Announcement
18 Sep 26 Routine Rule 2.9 Announcement
18 Sep 26 Holding Holding(s) in Company
16 Sep 26 Results Half-year Results
H1 2026 revenue up 4% to £115.5m; adjusted EBITDA up 8% but reported profit down 96% due to £12.4m exceptional items.
+0.2%
10 Sep 26 Holding Holding(s) in Company
07 Sep 26 Holding Holding(s) in Company
01 Sep 26 Rule 26 Disclosure
AMS and H.B. Fuller enter clean team agreement for integration planning in recommended cash acquisition.
−0.5%
01 Sep 26 Holding Holding(s) in Company
28 Aug 26 Routine Rule 2.9 Announcement
27 Aug 26 Holding Holding(s) in Company
26 Aug 26 Holding Holding(s) in Company
19 Aug 26 Holding Holding(s) in Company
17 Aug 26 Holding Holding(s) in Company
14 Aug 26 Routine Rule 2.9 Announcement
14 Aug 26 Holding Holding(s) in Company
14 Aug 26 Holding Holding(s) in Company
14 Aug 26 Holding Holding(s) in Company
12 Aug 26 Results of Court Meeting and General Meeting
H.B. Fuller acquisition of AMS approved by shareholders at Court and General Meetings held 12 August 2026.
+0.0%
31 Jul 26 Holding Holding(s) in Company
23 Jul 26 Routine Rule 2.9 Announcement
20 Jul 26 Holding Holding(s) in Company
20 Jul 26 Publication of Scheme Document
Scheme Document published for AMS shareholders to vote on H.B. Fuller's recommended cash acquisition.
+0.7%
20 Jul 26 Trading update Half Year 2026 Trading Update
H1 2026 revenue £115.2m, up 3.9% on prior year, but de-stocking impacted sales.
+0.7%
16 Jul 26 Routine Rule 2.9 Announcement
06 Jul 26 Routine Rule 2.9 Announcement
03 Jul 26 Holding Holding(s) in Company
01 Jul 26 Routine Rule 2.9 Announcement
30 Jun 26 Routine Rule 2.9 Announcement
29 Jun 26 Routine Rule 2.9 Announcement
29 Jun 26 Holding Holding(s) in Company
25 Jun 26 Director dealing Director/PDMR Shareholding
25 Jun 26 Offer Recommended Cash Acquisition
H.B. Fuller to acquire AMS for 285p per share, valuing the company at £659m, representing a 34.8% premium to the pre-announcement closing price.
+16.0%
18 Jun 26 Extension of PUSU Deadline
PUSU deadline for H.B. Fuller takeover approach extended to 2 July 2026 from 18 June.
+0.4%
17 Jun 26 Result of AGM
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company's Annual General Meeting held today at 11 am at the Offices of Inv
+5.6%
17 Jun 26 Routine Rule 2.9 Announcement
17 Jun 26 Routine Notice of AGM
16 Jun 26 Routine Rule 2.9 Announcement
11 Jun 26 Routine Rule 2.9 Announcement
08 Jun 26 Routine Rule 2.9 Announcement
04 Jun 26 Routine Form 8 (OPD)
27 May 26 Routine Rule 2.9 Announcement
26 May 26 Routine Rule 2.9 Announcement
26 May 26 Routine Form 8.3 - Advanced Medical Solutions Group plc
21 May 26 Holding Holding(s) in Company
21 May 26 Statement re Advanced Medical Solutions Group plc
H.B. Fuller submitted all-cash proposal for AMS on 30 April; discussions ongoing, firm offer decision due 18 June 2026.
+3.3%
21 May 26 Routine Rule 2.9 Announcement
21 May 26 Disclosure Table
The following are today's changes to the Disclosure Table:
+3.3%
21 May 26 Offer Statement re Possible Offer
H.B. Fuller made unsolicited cash offer proposal on 30 April; discussions ongoing, firm offer decision required by 18 June.
+3.3%
18 May 26 Disclosure Table
The following are today's changes to the Disclosure Table:
−18.4%
18 May 26 Response to 2.8 Announcement
TA Associates confirms it does not intend to make an offer for AMS and is bound by Rule 2.8 restrictions.
−18.4%
15 May 26 Offer No Intention to Make an Offer for AMS
TA Associates confirms it does not intend to make an offer for AMS following earlier takeover approach consideration.
−3.5%
15 May 26 Routine Notice of AGM
14 May 26 Routine Rule 2.9 Announcement
08 May 26 Routine Rule 2.9 Announcement
06 May 26 Routine Rule 2.9 Announcement
01 May 26 Routine Rule 2.9 Announcement
29 Apr 26 Routine Form 8 (OPD)(a) - dvanced Medical Solutions Group plc
28 Apr 26 Routine Rule 2.9 Announcement
27 Apr 26 Routine Rule 2.9 Announcement
24 Apr 26 Routine Rule 2.9 Announcement
23 Apr 26 Routine Rule 2.9 Announcement
22 Apr 26 Routine Rule 2.9 Announcement
21 Apr 26 Routine Rule 2.9 Announcement
20 Apr 26 Routine Doc re.Invalid RNS 1690B
20 Apr 26 Routine Form 8 - Advanced Medical Solutions Group plc
20 Apr 26 Routine Form 8 (OPD) - Advanced Medical Solutions Group
20 Apr 26 Disclosure Table
The following are today's changes to the Disclosure Table:
+16.2%
20 Apr 26 Offer Statement re Possible Offer
AMS in discussions with TA Associates regarding a possible offer for the company.
+16.2%
08 Apr 26 Holding Holding(s) in Company
31 Mar 26 Routine Total Voting Rights
18 Mar 26 Results Unaudited Preliminary Results
Record revenue of £228.9m, up 29%, with adjusted EBITDA up 24% to £49.9m and dividend increased 10%.
−0.3%
10 Mar 26 Holding Holding(s) in Company
06 Mar 26 Routine Block listing Interim Review
02 Mar 26 Routine Total Voting Rights
30 Jan 26 Routine Total Voting Rights
28 Jan 26 Holding Holding(s) in Company
15 Jan 26 Trading update Full Year 2025 Trading Update
Full year 2025 revenues of £228.5m and EBITDA of £49.5-£50.0m, ahead of 2024 driven by surgical products.
+0.9%
02 Jan 26 Routine Total Voting Rights
28 Nov 25 Routine Total Voting Rights
24 Nov 25 Holding Holding(s) in Company
10 Nov 25 Holding Holding(s) in Company
31 Oct 25 Routine Total Voting Rights
27 Oct 25 Upcoming Investor Conferences
AMS to attend investor conferences in November and December 2025.
−1.8%
16 Oct 25 Holding Holding(s) in Company
16 Oct 25 Holding Holding(s) in Company
08 Oct 25 Director dealing Director/PDMR Shareholding

Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note